Allegheny Financial Group’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $18.1K | Hold |
20,000
| – | – | ﹤0.01% | 247 |
|
|
2025
Q1 | $9.03K | Hold |
20,000
| – | – | ﹤0.01% | 230 |
|
|
2024
Q4 | $10.1K | Hold |
20,000
| – | – | ﹤0.01% | 229 |
|
|
2024
Q3 | $18.1K | Hold |
20,000
| – | – | ﹤0.01% | 240 |
|
|
2024
Q2 | $19.9K | Hold |
20,000
| – | – | 0.01% | 219 |
|
|
2024
Q1 | $29.6K | Hold |
20,000
| – | – | 0.01% | 203 |
|
|
2023
Q4 | $21.8K | Hold |
20,000
| – | – | 0.01% | 208 |
|
|
2023
Q3 | $23.6K | Buy |
+20,000
| New | +$23.6K | 0.01% | 190 |
|
|
2023
Q2 | – | Sell |
-20,000
| Closed | -$30K | – | 157 |
|
|
2023
Q1 | $30K | Hold |
20,000
| – | – | 0.01% | 161 |
|
|
2022
Q4 | $23.4K | Hold |
20,000
| – | – | 0.01% | 165 |
|
|
2022
Q3 | $22K | Hold |
20,000
| – | – | 0.01% | 156 |
|
|
2022
Q2 | $32K | Hold |
20,000
| – | – | 0.01% | 163 |
|
|
2022
Q1 | $31K | Hold |
20,000
| – | – | 0.01% | 159 |
|
|
2021
Q4 | $49K | Hold |
20,000
| – | – | 0.02% | 156 |
|
|
2021
Q3 | $50K | Hold |
20,000
| – | – | 0.02% | 150 |
|
|
2021
Q2 | $57K | Hold |
20,000
| – | – | 0.03% | 152 |
|
|
2021
Q1 | $47K | Hold |
20,000
| – | – | 0.03% | 101 |
|
|
2020
Q4 | $35K | Buy |
+20,000
| New | +$35K | 0.02% | 130 |
|